肝胆膵領域の臨床病理学的，分子生物学的研究

担当メンバー：田中麻理子、安永瑛一

肝胆膵腫瘍の病理形態学的特徴と分子生物学的性質を照らし合わせた発癌過程の解明や患者層別化の指標の同定などを研究しています。

 

＜参考文献＞

  1. PRKACA/PRKACB Fusions in Pancreatobiliary Intraductal Oncocytic Papillary Neoplasms Including Those With Atypical Morphology: An Analysis of 22 Cases Expanding Morphologic Spectrum. Tanaka M, Takeshita K, Kunita A, Hasegawa K, Ushiku T. Am J Surg Pathol 2024; 48; 1032-1040.
  2. Yasunaga Y, Tanaka M (co-first), Arita J, Hasegawa K, Ushiku T. Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity. Hum Pathol 2024; 150; 51-57.
  3. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Masugi Y, Takamatsu M, Tanaka M(co-first), Hara K, Inoue Y, Hamada T, Suzuki T, Arita J, Hirose Y, Kawaguchi Y, Nakai Y, Oba A, Sasahira N, Shimane G, Takeda T, Tateishi K, Uemura S, Fujishiro M, Hasegawa K, Kitago M, Takahashi Y, Ushiku T, Takeuchi K, Sakamoto M; GTK Pancreatic Cancer Study Group in Japan. J Pathol Clin Res 2023; 9; 339-353.
  4. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression. Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T. Liver Int 2022, 42; 2329-2340.
  5. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. Tanaka M, Shinozaki-Ushiku A, Kunita A, Yasunaga Y, Akamatsu N, Hasegawa K, Ushiku T. Pathol Int 2022, 72; 411-418.
  6. Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes. Tanaka M, Yamauchi N, Ushiku T, Shibahara J, Hayashi A, Misumi K, Yasunaga Y, Morikawa T, Kokudo T, Arita J, Sakamoto Y, Hasegawa K, Fukayama M. Am J Surg Pathol 2019; 43; 1180-1190.
  7. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. Tanaka M, Shibahara J, Ishikawa S, Ushiku T, Morikawa T, Shinozaki-Ushiku A, Hayashi A, Misumi K, Tanaka A, Katoh H, Sakuma K, Kokudo T, Inagaki Y, Arita J, Sakamoto Y, Hasegawa K, Fukayama M. Virchows Arch. 2019;474(1):39-46.
  8. Pancreatic Lipomatous Hamartoma: A Hitherto Unrecognized Variant. Tanaka M, Ushiku T, Ikemura M, Takazawa Y, Igari T, Shimizu M, Yamaguchi H, Fukushima N, Sakuma K, Arita J, Sakamoto Y, Hasegawa K, Watadani T, Nakai Y, Koike K, Fukayama M. Am J Surg Pathol. 2018;42(7):891-897.
  9. EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis. Tanaka M, Ishikawa S, Ushiku T, Morikawa T, Isagawa T, Yamagishi M, Yamamoto H, Katoh H, Takeshita K, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Oncotarget. 2017;8(59):99552-99566.
  10. Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.Abe H, Hayashi A, Kunita A, Sakamoto Y, Hasegawa K, Shibahara J, Kokudo N, Fukayama M. Int J Clin Exp Pathol. 2015;8(3):2763-70.
  11. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M. Oncogene. 2014;8;33(19):2454-63.
  12. Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior.Hayashi A, Yamauchi N, Shibahara J, Kimura H, Morikawa T, Ishikawa S, Nagae G, Nishi A, Sakamoto Y, Kokudo N, Aburatani H, Fukayama M. PLoS One. 2014 Mar 10;9(3):e91330.
  13. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M. J Histochem Cytochem. 2011;59(10):942-52.
  14. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M. Virchows Arch. 2011;459(1):73-80.
  15. Intraductal oncocytic papillary neoplasm of the bile duct: clinicopathologic and immunohistochemical characteristics of 6 cases. Tanaka M, Fukushima N, Noda N, Shibahara J, Kokudo N, Fukayama M. Hum Pathol. 2009;40(11):1543-52.
  16. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Yamauchi N1, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M. Mod Pathol. 2005 Dec;18(12):1591-8.